CALIPER LIFE SCIENCES TO ACQUIRE XENOGEN

Caliper Life Sciences, Inc., a leading provider of products and services for drug discovery research, and Xenogen Corporation, a maker of advanced imaging systems including instruments, biological solutions and software designed to accelerate drug discovery and development, today announced their definitive agreement to merge. Under the agreement, Caliper will issue common stock and warrants, currently valued at approximately $80 million, in exchange for all of Xenogen's equity securities outstanding at the closing.
PR Newswire